Incorrect to say no provision made for vaccination expenditure: FinMin

'Amount of Rs 35,000 crore shown under Demand for Grants No. 40, titled 'Transfers to States' ; use of this Demand for Grants has several administrative advantages,' says Ministry of Finance

Coronavirus vaccine, covid-19, vaccination
Representational image
Press Trust of India New Delhi
3 min read Last Updated : May 10 2021 | 3:41 PM IST

The finance ministry on Monday said provisioning Rs 35,000 crore-expenditure for vaccines in the Union Budget for FY22 under the title 'Transfers to States' does in no way inhibit the central government from using the funds to buy COVID-19 shots.

The amount of Rs 35,000 crore provided in the Union Budget for fiscal year starting April 1, 2021 (FY22) under the Demand for Grants No. 40, titled 'Transfers to States' has been done for several administrative advantages, including expenditure under such head being exempted from the quarterly control restrictions.

Also, it allows the Union government to procure the vaccines and pass them on to the states as grants in kind.

Refuting reports that no provision for expenditure on COVID-19 vaccination has been done by the central government, the finance ministry said, "vaccines have actually been, and are being, procured by and paid for by the Centre through this head of account (Demand for Grants No.40 Transfers to States)".

Since expenditure on vaccine is one-off expenditure outside the normal Centrally-Sponsored Schemes of the health ministry, separate funding ensures easy monitoring and management of these funds, the ministry noted.

The amount provided under this head for vaccinations is operated by the Ministry of Health. Vaccines are passed on to the states as grants in kind and the actual administration of vaccines is being done by states, it said.

Further, there is enough administrative flexibility to change the nature of the scheme between grants in kind and other forms of grants, it said in a statement.

"The use of the Demand titled 'Transfers to States' in no way implies that expenditure cannot be incurred by the Centre," the ministry said.

Currently, COVID-19 vaccines are being provided free of cost by the Centre to those who are 45 years of age and above and to all frontline workers.

The Centre has so far provided more than 17.56 crore vaccine doses to states/ UTs free of cost.

The Centre has placed total orders of 26.60 crore doses for Rs 3,639.67 crore with the Serum Institute of India which is manufacturing Covishield vaccine while an order for 8 crore doses involving an amount of Rs 1,104.78 crore has been placed with Bharat Biotech for Covaxin.

India is facing the world's worst outbreak of COVID-19 cases with more than 3 lakh new daily cases being reported for two weeks now and the new cases reached more than 4 lakh daily over the weekend. More than 2.46 lakh people in India have died from the virus infection.

Public health system is buckling under the weight of surging infections and deaths, with several parts of the country reporting shortage of hospital beds, medical oxygen, medicines and vaccines.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus Vaccine

First Published: May 10 2021 | 3:38 PM IST

Next Story